您当前所在的位置:首页 > 产品中心 > 产品信息
Ketoconazole_分子结构_CAS_65277-42-1)
点击图片或这里关闭

Ketoconazole

产品号 DB01026 公司名称 DrugBank
CAS号 65277-42-1 公司网站 http://www.ualberta.ca/
分子式 C26H28Cl2N4O4 电 话 (780) 492-3111
分子量 531.43092 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 899

产品价格信息

请登录

产品别名

标题
Ketoconazole
IUPAC标准名
1-[4-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one
IUPAC传统名
nizoral shampoo
商标名
Nizoral a-D
Nizoral
Extina
Fungoral
Ketoderm
Ketoisdin
Ketozole
Nizoral Cream
Nizoral Shampoo
Nizoral a-D Shampoo
Orifungal
Orifungal M
Sebazole
Fungarest
Panfungol
别名
Ketoconazol [INN-Spanish]
Ketoconazolum [INN-Latin]
Ketoconazole [Usan:Ban:Inn:Jan]
ketoconazole
Ketoconazol
Ketocanazole
2%

产品登记号

CAS号 65277-42-1

产品性质

疏水性(logP) 4
溶解度 0.0866 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. [PubChem]
Indication For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
Pharmacology Ketoconazole, like clotrimazole, fluconazole, itraconazole, and miconazole, is an imidazole antifungal agent.
Toxicity Hepatotoxicity, LD50=86 mg/kg (orally in rat)
Affected Organisms
Fungi
Biotransformation Hepatic
Absorption Moderate
Half Life 2 hours
Protein Binding 99% (in vitro, plasma protein binding)
References
Goeders NE, Peltier RL, Guerin GF: Ketoconazole reduces low dose cocaine self-administration in rats. Drug Alcohol Depend. 1998 Dec 1;53(1):67-77. [Pubmed]
Berwaerts J, Verhelst J, Mahler C, Abs R: Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol. 1999 Jun;13(3):175-82. [Pubmed]
Kazy Z, Puho E, Czeizel AE: Population-based case-control study of oral ketoconazole treatment for birth outcomes. Congenit Anom (Kyoto). 2005 Mar;45(1):5-8. [Pubmed]
Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE: A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002 Nov-Dec;15(6):434-41. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Goeders NE, Peltier RL, Guerin GF: Ketoconazole reduces low dose cocaine self-administration in rats. Drug Alcohol Depend. 1998 Dec 1;53(1):67-77. Pubmed
  • Berwaerts J, Verhelst J, Mahler C, Abs R: Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol. 1999 Jun;13(3):175-82. Pubmed
  • Kazy Z, Puho E, Czeizel AE: Population-based case-control study of oral ketoconazole treatment for birth outcomes. Congenit Anom (Kyoto). 2005 Mar;45(1):5-8. Pubmed
  • Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE: A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002 Nov-Dec;15(6):434-41. Pubmed